Guidewire Named One of Highest-Rated Public Cloud Computing Companies to Work For
Guidewire Software, Inc. (NYSE: GWRE), a provider of the industry platform Property and Casualty (P&C) insurers rely on, was again recognized as one of the 25 Highest Rated Public Cloud Computing Companies To Work For in a new list released by Battery Ventures, a global investment firm, with data specifically provided by Glassdoor*, one of the world’s largest job and recruiting sites. The list highlights 25 publicly traded companies—all business-to-business cloud companies--where employees report the highest levels of satisfaction at work, according to employee feedback shared on Glassdoor. This is Guidewire’s second consecutive appearance on the list.
This distinction placed Guidewire at number 5 (out of 25 total) with an overall company rating of 4.4. The broader average across Glassdoor is 3.4. Guidewire’s CEO, Marcus Ryu, reflects a 97% approval rating on Glassdoor—compared to an average of 69% for all 900,000 employers on the site--and the company has an 88 percent positive business-outlook rating, again based on feedback shared by employees. The broader Glassdoor average is 49%. A positive business outlook means employees believe business will improve in the next six months.
“The public companies on this list have not only scaled their products, teams and business functions—but they’ve managed to scale culture,” said Neeraj Agrawal, a Battery general partner who specializes in cloud investing. “We view these rankings as a key indicator of company health and longevity, and we hope all companies on this list view it as an honor to be included.”
“It was also more difficult to make the list this year, compared with last year,” Agrawal added. Battery and Glassdoor also released a similar list of the 50 Highest-Rated Private Cloud Computing Companies to Work For.
“The Guidewire team is gratified to be considered a peer of these distinguished companies, who are applying public cloud computing to respond to enterprise demands for standardization, simplification, and acceleration,” said Marcus Ryu, CEO and co-founder, Guidewire Software. “This work has moral urgency for Guidewire as well because the industry we serve, property-casualty insurance, plays a critical social role in protecting individuals and businesses in an uncertain world. This recognition is another milestone in our journey to become the most broadly adopted and trusted cloud-based platform for the industry.”
“We are actively recruiting to fill a wide variety of positions across our 26 offices around the world,” said Helen Reid, vice president, Global Human Resources and Administration. “Whether at our Foster City headquarters, second largest development center in Ireland, or offices across Europe, Canada, the U.S., Latin America, and Asia Pacific, Guidewire provides compelling, challenging, and professionally satisfying career options to consider.” For the latest career opportunities and to learn more about life at Guidewire, visit careers.guidewire.com.
*By a company name, denotes a Battery investment. For a full list of all Battery investments and exits, please click here .
**Views contained herein are for informational purposes only and should neither be considered investment advice nor construed or used as an offer and/or recommendation to buy or sell a security.
About Battery Ventures
Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
About Guidewire Software
Guidewire delivers the industry platform that Property and Casualty (P&C) insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and partner ecosystem to enable our customers to run, differentiate, and grow their business. We are privileged to serve more than 350 companies in 32 countries. For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC.
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005247/en/
Contact information
Diana Stott
Director, Communications
Guidewire Software, Inc.
+1.650.356.4941
dstott@guidewire.com
Megan Dyer Maxwell
GMK Communications for Battery Ventures
megan@gmkcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom